Our Private Equity Group is considered the go-to practice for complex, bespoke and firm-defining transactions. With clients ranging from the world’s leading institutional asset managers to prominent middle-market private equity and growth equity firms, we offer comprehensive advice to general partners, limited partners, co-investors and other equity stakeholders, as well as portfolio companies, lenders and financial sponsor groups. The depth and continuity of our relationships across the industry gives us a nuanced understanding of each client’s objectives and allows us to provide seamless, efficient counsel across the investment lifecycle.
SOFIE Biosciences to Receive Strategic Growth Investment From Trilantic North America
- Client News
- January 28, 2024
Paul, Weiss is advising SOFIE Biosciences, a Positron Emission Tomography (PET) radiopharmacy and contract development and manufacturing organization, in a substantial strategic growth investment made by global private equity firm Trilantic North America. Trilantic’s investment will be made in partnership with SOFIE’s founding team, who will retain a meaningful equity stake and continue to lead the business. Financial terms of the transaction were not disclosed. The transaction is expected to close later in 2024, subject to customary closing conditions and regulatory approvals.
The Paul, Weiss team is led by corporate partner Jeffrey Marell, tax partner Scott Sontag and corporate counsel Ji Lu, and includes corporate counsel Jason Tyler; executive compensation partner Jarrett Hoffman and counsel Sasha Belinkie; litigation partners Jaren Janghorbani and Aidan Synnott; intellectual property partner Claudine Meredith-Goujon; and environmental counsel William O'Brien.